Collaboration

#Artificial intelligence (AI) #Cancer research #Collaboration #Oncology #Precision medicine #The Institute of Cancer Research #Vivan Therapeutics

AI discovery collaboration targets precision cancer drugs

Researchers will combine expertise in drug discovery, artificial intelligence (AI), and experimental cancer models and platforms in a new programme to design the precision cancer drugs of the future. Under an academic and commercial collaboration between The Institute of Cancer Research, London, the Bellvitge Biomedical Research… Read More

#Cancer Research #News

#Bristol Myers Squibb #Collaboration #Evotec #Neurodegenerative disorders #Neuroscience

Evotec and BMS enter drug discovery licence agreement

Evotec and Bristol Myers Squibb (BMS) have entered into an exclusive global licence agreement, extending their neuroscience partnership. The agreement covers selected late-stage discovery programmes that were developed and progressed within the collaboration between the two companies. Evotec and BMS originally entered their neurodegeneration… Read More

#News

AI drug
#Artificial intelligence (AI) #Biopharmaceuticals #Collaboration #Influenza #Poolbeg Pharma

AI-led programme identifies multiple influenza drug targets 

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a breakthrough in its influenza AI Programme with CytoReason.   Poolbeg has been working with CytoReason since March 2022. Poolbeg’s disease progression data from influenza human challenge… Read More

#News

Peptide
#Collaboration #Contract Research Organisations (CROs) #IRBM #Merck #Partnership #Peptides

IRBM and Merck extend peptide therapeutics collaboration

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area. “The success of this collaboration is reflected by the outstanding achievements in the… Read More

#Business & Investment #News

Cryo-EM
#Advanced Therapy Medicinal Products (ATMPs) #Blood products #Cell and gene therapy #Collaboration #Cryopreservation #Cyto-care.eu #Partnership #SCTbio

Companies collaborate to improve cell therapy cryopreservation

Contract development and manufacturing organisation (CDMO) SCTbio and cell therapy company Cyto-care.eu have teamed up with the aim of improving the quality of cryopreservation in Europe. The goal of the collaboration is to address the critical need for efficient collection, cryopreservation, quality control and logistics capabilities… Read More

#News

Node structures in the central nervous system
#CNS #Collaboration #Nanopharmaceutics #PrecisionLife

Collaboration to accelerate and de-risk CNS clinical development 

PrecisionLife and Nanopharmaceutics have entered a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets.  This collaboration between PrecisionLife and Nanopharmaceutics uses mechanistic patient stratification biomarkers to inform clinical trial design and transform the lives of patients. … Read More

#News

#Cancer research #Collaboration #Data security #Flatiron Health #Lifebit #Oncology #Partnership #Real world data

Partnership hopes to accelerate cancer data research

Lifebit and Flatiron Health have announced a multi-year strategic partnership with the aim of improving scientific discoveries by learning from the experience of  cancer patients. Health data generated by hospitals, healthcare providers, research organisations and clinical trials hold the potential to advance research and innovation, improve… Read More

#Business & Investment #News

#Artificial intelligence (AI) #Automation / robotics #Collaboration #Eli Lilly #Partnership #XtalPi

Eli Lilly and XtalPi sign AI drug discovery collaboration

Eli Lilly and XtalPi have entered an AI drug discovery collaboration of up to $250 million in upfront and milestone payments. XtalPi is a pharmaceutical technology company with operations in China and the US. The collaboration will use XtalPi’s integrated AI and robotics platform… Read More

#News

#Biopharma #Biotech #Clarivate #Collaboration #Investment #Partnership

Biopharma investment drops by nearly 50% in 2022

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff. The… Read More

#Business & Investment #News #Trends & Analysis

Science and research of the universe; quantum science
#Collaboration #Deep learning #Deep tech #Life sciences #Quantum computing #Research

Start-up accelerator to unlock potential in quantum science 

BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating life science research, has launched a new deep tech accelerator start-up programme, the Deep Tech Lab – Quantum, to propel emergent and disruptive quantum science and biotechnology solutions toward the marketplace.   Deep tech and quantum science have… Read More

#News

#Collaboration #Drug development #Drug discovery #License agreement #Mergers and acquisitions

This week in drug discovery (8-12 May)

News round-up for 8-12 May by DDW Digital Content Editor Diana Spencer. Inspired by the relaunch of PerkinElmer’s Life Science and Diagnostics business this week as Revvity, my top five news story this week all relate to new drug discovery business developments. See below for the… Read More

#News

Peptide
#Bayer #Bicycle Therapeutics #Collaboration #Oncology #Partnership #Peptides #Radiochemistry

Bayer and Bicycle collaborate on bicyclic peptides

Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialise Bicycle radioconjugates for multiple oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured and bind to targets with high affinity and selectivity,… Read More

#Cancer Research #News

Handshake
#Autoimmune disease #Collaboration #License agreement #Tay Therapeutics #VYNE Therapeutics

Tay licenses oral BET inhibitor to VYNE Therapeutics

UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2. Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021. The out-licensing… Read More

#Business & Investment #News

#ABL Diagnostics #Collaboration #Cytomegalovirus #Diagnostics #HIV #Human Papillomavirus #Infectious diseases #Laboratory #Microbiology #Roche #Tuberculosis #Viral hepatitis

Roche and ABL Diagnostics expand to South African laboratories  

Roche Diagnostics and ABL Diagnostics have launched a distribution partnership which will see Roche supplying ABLD products to South African laboratories.   Roche now has exclusive rights to distribute products, including the ABL DeepChek assays to laboratories implementing microbiology applications. These applications include HIV, Tuberculosis, Cytomegalovirus, Viral… Read More

#News

Two scientists working in a research laboratory
#BioGenCell #Clinical trial #Collaboration #Diabetes #Partnership #Phase II trial #University of California San Francisco

Industry-academia alliance targets chronic limb-threatening ischaemia

BioGenCell has partnered with the University of California San Francisco (UCSF) as part of the company’s Phase II clinical trials. The partnership will focus on the impact of BioGenCell’s treatment on those with chronic limb-threatening ischaemia (CLTI also known as CLI), a debilitating condition commonly associated… Read More

#News

Test for AMD
#AI / data analytics / healthtech / informatics #Boehringer Ingelheim #Collaboration #Geographic atrophy #Partnership #RetinaAI

Partners use AI tools to advance novel drugs for geographic atrophy

A partnership between RetinAI Medical and Boehringer Ingelheim aims to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, advanced form of age-related macular degeneration and a leading cause… Read More

#Business & Investment #News